# Hikma and Vectura sign global agreement to develop generic versions of GSK's Ellipta portfolio

Hikma Pharmaceuticals signed an agreement with Vectura Group for the global development and commercialization of generic versions of GSK's Ellipta portfolio, using Vectura's Open-Inhale-Close dry powder inhaler device. Hikma made an upfront payment of $15 million.

- Type: Partnership
- Announced: 2018-11-08
- Value: $15.0M
- Status: announced
- Products: generic dry powder inhalers, respiratory medicines
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Vectura AS](https://endata.com/companies/5555.md) (partner)
- [Hikma Pharmaceuticals](https://endata.com/companies/22160.md) (partner)

## Sources

- [hikma.com](https://www.hikma.com/news/hikma-announces-global-agreement-with-vectura-to-develop-generic-versions-of-gsk-s-ellipta-portfolio/), 2018-11-08: "This agreement leverages the investment we have made and the experience we have gained through our generic Advair Diskus programme."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.